Axillary Lymph Node Dissection in Angiosarcomas of the Breast: An Asian Institutional Perspective.
Journal
Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
01
2020
accepted:
25
02
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
18
4
2020
Statut:
epublish
Résumé
Angiosarcomas of the breast (ASB) are rare, making up to less than 8% of all angiosarcomas. The surgical management for this disease continues to vary throughout centres worldwide due to the current limited evidence. We aim to examine the necessity of axillary lymph node dissection in this pathology through a retrospective study of axillary metastasis and recurrence patterns in patients treated at our institution. A retrospective review of a prospectively-maintained database was performed. All adult patients with a histologically confirmed diagnosis of ASB seen at the National Cancer Centre Singapore between 2006 and 2019 were identified. Axillary lymph node status, treatment, survival, and recurrence data were collated. Thirteen patients were identified with a confirmed diagnosis of ASB, of which there were 11 primary and 2 secondary angiosarcoma cases. Eight patients had some form of axillary lymph node dissection and 5 did not. No positive nodes were found in any examined axillary nodes despite high median number of nodes harvested (13, range 8-24). 5/13 patients had disease progression, of whom none had locoregional recurrence to the axilla. ASB continues to be rare and recurrent and presents as a challenge to treat. Axillary lymph node involvement is most likely not present in a majority of patients. Prophylactic removal is unwarranted in patients presenting without lymph node involvement due to the lack of axillary metastasis.
Identifiants
pubmed: 32300278
doi: 10.1155/2020/4890803
pmc: PMC7136812
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4890803Informations de copyright
Copyright © 2020 Sharanniyan Ragavan et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
World J Surg. 2011 Nov;35(11):2417-21
pubmed: 21882024
J Surg Oncol. 2006 Oct 1;94(5):368-74
pubmed: 16967461
Breast Cancer Res Treat. 2007 Sep;105(1):81-5
pubmed: 17115110
Ann Diagn Pathol. 2009 Jun;13(3):147-50
pubmed: 19433291
Br J Radiol. 2017 Jul;90(1075):20170039
pubmed: 28471264
Breast. 2012 Aug;21(4):584-9
pubmed: 22305554
Medicine (Baltimore). 2018 Sep;97(39):e12513
pubmed: 30278541
Radiographics. 2007 Oct;27 Suppl 1:S125-30
pubmed: 18180222
Ann Surg. 1993 Jan;217(1):72-7
pubmed: 8424704
Curr Oncol. 2018 Feb;25(1):e50-e53
pubmed: 29507495
Nat Clin Pract Oncol. 2008 Dec;5(12):727-36
pubmed: 18936792
Cancer. 1988 Nov 15;62(10):2145-51
pubmed: 3179927
Am J Surg. 2012 Feb;203(2):156-61
pubmed: 21658671
Radiother Oncol. 2007 Dec;85(3):355-61
pubmed: 18023492
Cancer. 2007 Jul 1;110(1):173-8
pubmed: 17541936
Ann Surg Oncol. 2007 Jun;14(6):1953-67
pubmed: 17356953
Cancer. 1982 Nov 15;50(10):2000-3
pubmed: 6889910
Breast Cancer Res Treat. 2012 Apr;132(3):1081-8
pubmed: 22207278
Am J Clin Oncol. 2009 Dec;32(6):582-6
pubmed: 19581792
Breast Dis. 2018;37(3):133-138
pubmed: 29286911
Gland Surg. 2014 Feb;3(1):28-34
pubmed: 25083491
Cancer. 2005 Dec 15;104(12):2682-8
pubmed: 16288486
Cancer. 1965 Mar;18:352-61
pubmed: 14268437
Cancer. 2003 Apr 15;97(8):1832-40
pubmed: 12673708